Results 1 to 10 of about 320,384 (168)

Oxidative Stress, Insulin Resistance, Dyslipidemia and Type 2 Diabetes Mellitus

World Journal of Diabetes, 2015
Oxidative stress is increased in metabolic syndrome and type 2 diabetes mellitus (T2DM) and this appears to underlie the development of cardiovascular disease, T2DM and diabetic complications. Increased oxidative stress appears to be a deleterious factor
Surapon Tangvarasittichai
exaly   +2 more sources

Metabolic Dyslipidemia and Cardiovascular Outcomes in Type 2 Diabetes Mellitus: Findings From the Look AHEAD Study

Journal of the American Heart Association, 2021
Background Metabolic dyslipidemia (high triglyceride) and low high‐density lipoprotein cholesterol (HDL‐C) is highly prevalent in type 2 diabetes mellitus (T2DM).
Rexford S. Ahima, Arnaud D Kaze, Justin B Echouffo-Tcheugui   +2 more
exaly   +2 more sources

Endocannabinoids Produced by White Adipose Tissue Modulate Lipolysis in Lean but Not in Obese Rodent and Human

Frontiers in Endocrinology, 2021
White adipose tissue (WAT) possesses the endocannabinoid system (ECS) machinery and produces the two major endocannabinoids (ECs), arachidonoylethanolamide (AEA) and 2-arachidonoylglycerol (2-AG).
Chloé Buch, Tania Muller, Julia Leemput, Patricia Passilly-Degrace, Pablo Ortega-Deballon, Jean-Paul Pais de Barros, Bruno Vergès, Bruno Vergès, Tony Jourdan, Laurent Demizieux, Pascal Degrace   +10 more
doaj   +1 more source

Gut microbiota-bile acid crosstalk regulates murine lipid metabolism via the intestinal FXR-FGF19 axis in diet-induced humanized dyslipidemia

Microbiome, 2023
Background Diet-induced dyslipidemia is linked to the gut microbiota, but the causality of microbiota-host interaction affecting lipid metabolism remains controversial.
Hong-Tao Xu, Fang Fang, Kaizhang Wu, Jiangping Song, Yaqian Li, Xingyu Lu, Juncheng Liu, Liu-Yang Zhou, Wenqing Yu, Fei Yu, Jie Gao   +10 more
semanticscholar   +1 more source

Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook.

Atherosclerosis, 2023
Dyslipidemia refers to unhealthy changes in blood lipid composition and is a risk factor for atherosclerotic cardiovascular diseases (ASCVD). Usually, low-density lipoprotein-cholesterol (LDL-C) is the primary goal for dyslipidemia management.
V. Raja, C. Aguiar, Nasreen A. Alsayed, Yogeyaa S. Chibber, Hussein Elbadawi, Marat V. Ezhov, Michel P. Hermans, R. Pandey, K. Ray, L. Tokgözoğlu, Alberto Zambon, J. Berrou, M. Farnier   +12 more
semanticscholar   +1 more source

Dyslipidemia and Cardiovascular Disease: Current Knowledge, Existing Challenges, and New Opportunities for Management Strategies

Journal of Clinical Medicine, 2023
Cardiovascular disease is the leading cause of morbidity and mortality worldwide, and dyslipidemia is one of the major risk factors [...].
Zhi-Yong Du, Yan-Wen Qin
semanticscholar   +1 more source

Endothelial Function in Dyslipidemia: Roles of LDL-Cholesterol, HDL-Cholesterol and Triglycerides

Cells, 2023
Dyslipidemia is associated with endothelial dysfunction. Endothelial dysfunction is the initial step for atherosclerosis, resulting in cardiovascular complications.
Y. Higashi
semanticscholar   +1 more source

Prognostic utility of lipoprotein(a) combined with fibrinogen in patients with stable coronary artery disease: a prospective, large cohort study

Journal of Translational Medicine, 2020
Background Elevated lipoprotein(a) [Lp(a)] and fibrinogen (Fib) are both associated with coronary artery disease (CAD). The atherogenicity of Lp(a) can be partly due to the potentially antifibrinolytic categories. We hypothesize that patients with higher
Yan Zhang, Jing-Lu Jin, Ye-Xuan Cao, Hui-Hui Liu, Hui-Wen Zhang, Yuan-Lin Guo, Na-Qiong Wu, Ying Gao, Qi Hua, Yan-Fang Li, Rui-Xia Xu, Chuan-Jue Cui, Geng Liu, Qian Dong, Jing Sun, Jian-Jun Li   +15 more
doaj   +1 more source

Therapeutic potential of a novel peripherally restricted CB1R inverse agonist on the progression of diabetic nephropathy

Frontiers in Nephrology, 2023
ObjectiveThis study assessed the efficacy of INV-202, a novel peripherally restricted cannabinoid type-1 receptor (CB1R) inverse agonist, in a streptozotocin-induced type-1 diabetes nephropathy mouse model.MethodsDiabetes was induced in 8-week-old C57BL6/
Laetitia Jacquot, Océane Pointeau, Célia Roger-Villeboeuf, Patricia Passilly-Degrace, Rim Belkaid, Isaline Regazzoni, Julia Leemput, Chloé Buch, Laurent Demizieux, Bruno Vergès, Pascal Degrace, Glenn Crater, Tony Jourdan   +12 more
doaj   +1 more source

Oxidative Stress, Atherogenic Dyslipidemia, and Cardiovascular Risk

Biomedicines, 2023
Oxidative stress is the consequence of an overproduction of reactive oxygen species (ROS) that exceeds the antioxidant defense mechanisms. Increased levels of ROS contribute to the development of cardiovascular disorders through oxidative damage to ...
J. Vekić, Kristine Stromsnes, Stefania Mazzalai, A. Zeljković, Manfredi Rizzo, J. Gambini   +5 more
semanticscholar   +1 more source